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With the advancement of high-throughput technology, transcriptomic studies have 
been accumulated in the public domain. Meta-analysis combines multiple studies on a 
related hypothesis and improves the statistical power and reproducibility of single 
studies. However, a majority of existing meta-analysis methods only consider the 
statistical significance. We propose a novel method to categorize biomarkers by 
simultaneously considering statistical significance, biological significance (large 
effect size) and concordance patterns across studies, accounting for the complex study 
heterogeneity that exists in most meta-analysis problems. We conducted simulation 
studies and applied our method to Gynecologic and breast cancer RNA-seq data from 
The Cancer Genome Atlas to show its strength as compared to adaptively-weighted 
Fisher’s method. We found several major biomarker categories according to their 
cross-study patterns, and these categories are enriched in very different sets of 
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Chapter 1: Introduction 
Review of Relevant Literature 
Transcriptomics studies the complete set of RNA transcripts (both coding and non-
coding genes) in individuals under specific circumstances using high-throughput 
technologies such as microarray and RNA sequencing (RNA-seq). The most common 
use of transcriptome profiling is to search for differentially expressed (DE) genes 
which show differences in expression level between two or more conditions (Soneson 
and Delorenzi, 2013). Over the years, with the advancement and more affordable 
price of high-throughput genomic technologies, plenty of data sets have been 
accumulated in public domains such as The Cancer Genome Atlas (TCGA) from NIH 
National Cancer Institute (https://portal.gdc.cancer.gov/), Gene Expression Omnibus 
(GEO) from NCBI (http://www.ncbi.nlm.nih.gov/geo/) and Sequence Read Archive 
(SRA) from NCBI (https://www.ncbi.nlm.nih.gov/sra).  
Findings from single transcriptomic study are usually not reproducible because of 
limited sample size relative to large numbers of potential predictors (Ramasamy et al., 
2008). Meta-analysis is a set of statistical techniques and tools to combine 
information from multiple and related research studies and will potentially increase 
reproducibility and validity of single studies. Horizontal omics meta-analysis aims to 
combine different sample cohorts of the same omics data types (e.g. gene expression, 
genetic variants) (Tseng et al., 2012). For DE gene detection, there are three major 
categories of horizontal meta-analysis methods: combining P-values, combining 





individual study results is relatively simple approach and can accommodate different 
outcome types. For example, the famous Fisher’s method (Fisher,1932) sums up log-
transformed P-values obtained from differential expression analysis in individual 
studies. Instead of log-transformation, Stouffer’s method (1949) alternatively adopts 
an inverse normal transformation. Li and Tseng (2011) extended Fisher’s method and 
introduced an adaptively weighted Fisher’s method (AW-Fisher) to indicate which 
studies contribute to the evidence aggregation and elucidates heterogeneity in meta-
analysis. AW-Fisher searches all possible 0 or 1 weight for K individual study (a total 
of 2K -1 possibilities) to find the best adaptive weight with the smallest derived p-
value of the statistics.  
One limitation of combining p-values in meta-analysis method is that they only 
consider statistical significance (p-values) without considering the absolute 
magnitudes of effect size (a.k.a. fold change in genomic studies) in each study or the 
directionality of effect size across studies (i.e. concordance pattern). Fixed effects 
model (FEM) and random effects model (REM) are two most popular meta-analysis 
methods in combining effect sizes. Fixed effects model combines the estimated effect 
sizes from multiple studies assuming they share the same underlying true effect size 
plus measurement error in each study. Random effects model extends fixed effects 
model by allowing random effects for the inter-study heterogeneity in the model 
(Choi et al., 2003). Although random effects model can incorporate unknown inter-
study heterogeneities, both fixed effects model and random effects model only allow 
one single concordant pattern (either up or down-regulated) for one gene across all 






For genomics data, biological significance (large absolute value of effect sizes) and 
up-/down-regulated concordance are as important as the statistical significance (small 
p-values). Statistical significance is determined by magnitudes of effect size, variance 
of gene expression and sample size. On one hand, biological significance does not 
necessarily imply statistical significance when sample size is small and gene variation 
is large. For example, Gynecologic cancer is the fourth most common cancer in 
women and it has four different subtypes (National Cervical Cancer Coalition, 2019). 
One subtype, uterine carcinosarcoma (UCS), is a rare cancer that has relatively small 
sample size with limited statistical power. If we only consider statistical significance, 
many important genes would almost for sure be overlooked.  On the other hand, 
statistical significance does not reflect biological significance when p-value is small 
simply due to large sample size or small variance. For example, large cohorts find 
many housekeeping genes to be statistically significant but those findings have 
minimal practical usage when the actual magnitude of effect size is too small.   
One big challenge in genomic studies is how to interpret a large pool of DE gene 
findings. A common practice is to perform a pathway analysis by using Fisher’s exact 
test to see in what functional domains these DE genes are enriched (Hoasck et al., 
2003). However, for meta-analysis, top genes identified are of varying differential 
expression patterns across studies and biomarker categorization by their cross-study 
patterns become an important task. Ma et al. (2017) showed the biomarkers 





different pathways, facilitating improved interpretation and biological hypothesis 
generation.  
Overview of the Thesis 
To address these gaps in knowledge, we develop a new approach to categorize the 
biomarkers by simultaneously considering statistical significance, biological 
significance and concordance patterns across the studies. We propose two measures in 
this approach for both up and down-regulated patterns in the same gene thus allow the 
existence of possible discordant patterns among all studies. We conduct two 
simulation scenarios assessing both weight patterns and gene ranking to demonstrate 
the strength of our method. As compared to AW-Fisher, the proposed method 
identifies the correct weight patterns for those genes with possible discordant and 
rank higher the DE genes with possible biological significance but marginal statistical 
significance. Our pilot study focuses on meta-analyzing the RNA-seq data from the 
following five TCGA tumor types (Pan-Gyn): high-grade serous ovarian 
cystadenocarcinoma (OV), uterine corpus endometrial carcinoma (UCEC), cervical 
squamous cell carcinoma and endocervical adenocarcinoma (CESC), uterine 
carcinosarcoma (UCS), and invasive breast carcinoma (BRCA). Since the underlying 
truth is not known in real data, we performed a pathway enrichment analysis to 
evaluate our approach and provide biological insights to the future precision medicine 
in cancer treatment. A total of 26 weight categories of different biological 
significance, statistical significance and concordance patterns across studies were 
identified by our method. Each weight category implied different functional domains 





Relevance to Public Health and Biostatistics 
Heterogeneity is an essential factor to study and develop treatments for many 
diseases. For example, the risk of infecting COVID-19 is dependent on the 
characteristics of the infectious host, the susceptible host, and the environment. 
Similarly, the heterogeneity exists in transcriptomic data as a marked challenge of 
aggregating multiple studies. Simple aggregation of the data would overlook some 
critical information for investigating human diseases. Even if people know the 
existence of population heterogeneity, it is still commonly seen in real applications of 
precision medicine that patients having same type and stage of cancer are treated with 
the same treatment. In order to obtain more useful and credible information from 
meta-analysis while considering between study variation, we proposed sophisticated 
measures to categorize inter-study heterogeneous biomarkers by simultaneously 
considering biological significance (absolute magnitude of effect sizes), concordance 
(up-/down-regulated), and statistical significance (p-values) across multiple 












Chapter 2: Method 
Popular meta-analysis methods 
Microarray meta-analysis for DE gene detection is a commonly encountered 
application for integrating multiple studies on a related hypothesis and improving the 
statistical power and reproducibility of single studies. We will discuss two major 
types of statistical meta-analysis methods as follow: combining p-values and 
combining effect sizes.  
1. Combining p-values 
1A. Fisher’s method 
The combined Fisher’s statistic 𝑇𝐹𝑖𝑠ℎ𝑒𝑟 = −2 ∑ log(𝑃𝑘)
𝐾
𝑘=1  follows a χ2 distribution 
with 2K degrees of freedom under the null hypothesis (i.e. genes are not differentially 
expressed in all studies), where K studies are combined and 𝑃𝑘 is the p-value of study 
k, 1≤ k ≤ K. Smaller p-values contribute larger scores to the Fisher’s statistic. 
1B. Stouffer’s method 





the inverse cumulative distribution function of standard normal distribution. Similar 
to Fisher’s method, smaller p-values contribute more to the Stouffer’s score, but in a 
smaller magnitude.  
1C. Adaptively-Weighted Fisher (with biomarker categorization) 
Li and Tseng (2011) introduced an adaptively weighted Fisher’s method (AW-Fisher) 
that characterizes effective studies under a null hypothesis for each gene g is 





and study k, against an alternative hypothesis HA: at least one 𝜃𝑔𝑘 ≠ 0 in 1≤ k ≤ K 
study when integrating multiple genomic studies. 
To uncover inter-study heterogeneous gene expression patterns across studies, they 
started with the following weighted statistic: 
𝑈𝑔(𝑤𝑔) = − ∑ 𝑤𝑔𝑘𝑙𝑜𝑔(𝑝𝑔𝑘)
𝐾
𝑘=1 , 
where 𝑝𝑔k is the p-value of gene g in study k,𝑤𝑘 is the weight assigned to the kth 
study and 𝑤𝑔= (𝑤𝑔1, … , 𝑤𝑔𝐾). Under the null hypothesis that θ𝑔𝑘=0 ∀k, the p-value of 
the observed weighted statistic, 𝑝𝑈(𝑢𝑔(𝑤𝑔)), can be obtained for a given gene g and 
weight 𝑤𝑔. The adaptively-weight statistic was defined as the minimal p-value among 





where 𝑢𝑔(w) is the observed statistic for 𝑈𝑔(𝑤), and W is a prespecified search space, 
the choice of search space is W={w|𝑤𝑖𝜖{0,1}}, which results in an affordable 
computation of O(2𝐾 − 1) based on the norm of K≤10 in a microarray meta-analysis. 
The resulting weight reflects a natural biological interpretation of if a study 
contributes to the statistical significance of a gene.  
2. Combining effect size 
2A. Fixed effect model (FEM) 
The fixed effect model is given as 𝑇𝐹𝐸𝑀 = 𝜇 + 𝑘, 𝑘~ 𝑁(0, 𝑠𝑘
2),where 𝜇 is the 
overall mean and 𝑘 is a random error following a normal distribution with a variance 
𝑠𝑘
2 within certain study k.  





The random effect model is given as 𝑇𝑅𝐸𝑀 = 𝜇 + 𝛿𝑘 + 𝑘, 𝑘~𝑁(0, 𝑠𝑘
2), 𝛿𝑘~𝑁(0, 𝜏
2), 
where 𝜇 is overall mean, 𝑘 is a random error following a normal distribution with a 
variance 𝑠𝑘
2 within certain study k and 𝛿𝑘 is a second source of error following a 
normal distribution with a variance 𝜏2 between studies.  
Our proposed method for biomarker categorization in meta-analysis 
Suppose there are K transcriptomic studies, each study k (1≤k≤K) measures the gene 
expression of 𝑛𝑘 sample and G genes. In the simplest scenario, we compare the case 
and control samples in each study and identify the differentially expressed genes 
using popular methods such as limma (Ritchie et al. (2015)). After DE analysis, we 
obtain the effect size estimates (𝑙𝑜𝑔2𝐹𝐶𝑔𝑘) and p-values (𝑝𝑔𝑘) for each gene g 
(1≤g≤G) in each study k. We proposed the following two weighted statistics, one for 
up-regulated pattern and the other for down-regulated pattern, to look for the 
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+  𝑎nd 𝑤𝑔𝑘
−  is a weight of 0 or 1 assigned to the kth study for gth gene. 
log2FCgk is the calculated log2 fold change for gene g in study k. By default, 𝑤𝑔𝑘
+ =
0 for those studies with log2FCgk<0 and 𝑤𝑔𝑘
− = 0 for log2FCgk>0. pgk is the p-
value for gene g in study k outputted from the differential expression analysis. 𝑇𝑔(𝑤𝑔)
+  
and 𝑇𝑔(𝑤𝑔)





respectively. In this measure, we account for statistical significance, biological 
significance and concordance patterns. Note that for genes with concordant 
directionality across all studies (either up-regulated or down-regulated), we define the 
corresponding 𝑇𝑔(𝑤𝑔)
+ or 𝑇𝑔(𝑤𝑔)
−  in the other direction to be all zero. The weights in the 
other direction are also suppressed to zero for all studies. When only one study has an 
opposite direction, the statistics for the corresponding direction and the weight of the 
corresponding study are also zero.   
We will search all possible 0 or 1 weight for K individual study in each of the two 
weighted statistics and define the best concordant statistics 𝑅𝑔
+ and 𝑅𝑔
− as the 
maximum 𝑇𝑔(𝑤𝑔)
+ and  𝑇𝑔(𝑤𝑔)










𝑊+ 𝑎𝑛𝑑 𝑊− are pre-defined searching space for up- and down-regulated studies with 
aforementioned restrictions. The resulting weights in 𝑅𝑔
+ and 𝑅𝑔
− can then be used to 
categorize the biomarkers.  We denote the best weights as 𝑤𝑔
+∗and 𝑤𝑔
−∗, respectively.  
The biomarkers are categorized according to different best weight distribution among 
studies (i.e. by merging the information of 𝑤𝑔
+∗and 𝑤𝑔
−∗). Comparing to the AW 
Fisher’s method for gene ranking and biomarker categorization, our method has three 
significant advantages. Firstly, both biological significance and statistical significance 
are considered in our statistics. Secondly, the statistics prioritizes concordant genes 
across multiple studies and provides ranking for both up and down-regulated patterns. 
Finally, for discordant genes with both up and down-regulated patterns, we can use 
𝑅𝑔
+ and 𝑅𝑔













Chapter 3: Results 
Simulation 
Simulation setting 
We conducted simulations to demonstrate the strength of the proposed best 
concordance statistics in weight categorization and gene ranking compared to AW 
Fisher method under two simulation scenarios. 
Scenario 1. Assess weight patterns of both concordant and discordant genes 
We generated n=100 observations consisting of 50 cases and 50 controls in each of 
K=5 studies. We first sampled the baseline gene expression level 𝑋𝑔𝑖𝑘
′ independently 
for each observation i (1≤i≤100) from N(0, 𝜎𝑔𝑘
2 ), where 𝜎𝑔𝑘
2  was randomly drawn 
from {0.2, 0.3, 0.4, 0.5, 0.6} for each gene g (1≤g≤2000) in study k (1≤k≤5). We then 
sampled a total of 800 DE genes of eight differential expression patterns across 
studies (100 genes for each pattern) by using an indicator δgk ϵ {-1,0,1} for all 
G=2000 genes (See Table 4 for nine true differential expression gene patterns), where 
δgk =1 or -1 indicates gene g in study k is an up- or down-regulated DE gene, δgk =0 
indicates a non-DE gene. The rest 1200 genes are non-DE genes that have δgk =0 in 
all studies. When δgk =1 or -1, we sampled absolute effect size 𝜇𝑔𝑘from a uniform 
distribution in the range of [0.7,1] for gene g in study k. The gene expression of 
control samples is  𝑋𝑔𝑖𝑘 = 𝑋𝑔𝑖𝑘
′ , and the expression of case samples is 𝑌𝑔𝑖𝑘 = 𝑋𝑔𝑖𝑘
′ +
𝜇𝑔𝑘 ∗ 𝛿𝑔𝑘, for 1≤g≤2000, 1≤i≤50 and 1≤k≤5. For non-DE genes, 𝑌𝑔𝑖𝑘 = 𝑋𝑔𝑖𝑘 = 𝑋𝑔𝑖𝑘
′ . 
We applied both our method and AW-Fisher method to the simulated data for 





weight patterns (δgk). In addition, we also defined concordant DE genes as those up-
regulated or down-regulated in at least ⌊k/2⌋ studies (one DE gene can be 
concordant up and down in the same) and plotted the true number of concordant 
DE genes versus the top ranked genes by the statistics of each method (𝑅𝑔
+/𝑅𝑔
− in our 
method and p-value in AW-Fisher’s method).  
Scenario 2. Assess gene ranking   
In this scenario, we assessed the ranking of genes by our method and AW-Fisher 
method considering statistically significance, biological significance and concordance 
patterns across studies. We followed from scenario 1 and performed a second 
simulation by increasing the variance of gene expression 𝜎𝑔𝑘
2  to be randomly drawn 
from {4.3, 4.5, 4.4, 4.7, 4.2} for each gene g (1≤g≤2000) in study k (1≤k≤5). For our 
method, we used Rg =max (𝑅𝑔
+, 𝑅𝑔
−) to rank the genes. For assessment, we plotted the 
true number of DE genes versus the top ranked genes by the statistics of each method.  
Simulation results 
For simulation scenario 1, Table 1 shows number of genes with correct weight 
patterns by our method and AW-Fisher’s method. Both adaptively weighted Fisher’s 
method and our proposed measure perform equally well by almost perfectly assigning 
the correct weights to studies with indicator δgk =1 or -1 in all five studies 
(δ𝑔
(𝑘=1,2,3,4,5)
 =(1,1,1,1,1) or (-1,-1,-1,-1,-1)  )or first three studies k=1, 2, and 3 
(δ𝑔
(𝑘=1,2,3,4,5)
=(1,1,1,0,0) or (-1,-1,-1,0,0)). When discordance exists in the true DE 
gene patterns (e.g. δ𝑔
(𝑘=1,2,3,4,5)
 = (1,1,1,1,-1)), the adaptively weighted Fisher’s 





the contrary, our measures not only correctly assigned weights to DE genes, but also 
reflected up- and down-regulated concordance.  
Table 1 Number of corrected identified weight patterns by our method and AW-
Fisher’s method 
True weight pattern 
  
Number of genes with correct weight 
pattern by AW-Fisher’s method 
Number of genes with correct weight 





1,1,1,1,1 100 97 NA 
-1,-1,-1,-1,-1 100 NA 96 
1,1,1,1,-1 0 100 NA 
-1,-1,-1,-1,1 0 NA 98 
1,1,1,-1,-1 0 100 100 
-1,-1,-1,1,1 0 100 100 
1,1,1,0,0 99 100 NA 
-1,-1,-1,0,0 99 NA 100 
 
Among all the DE genes with the eight true weight patterns, there are a total of 600 
genes with concordant up-regulated pattern and 600 genes with concordant down-
regulated pattern. Figure 1 and 2 show that our method identified more true 
concordant (up or down-regulated) genes among the top ranked genes by 𝑅𝑔
+ or 𝑅𝑔
− as 






Figure 1. True number of concordant DE genes versus the top ranked genes by the 
statistics of 𝑅𝑔
+ in our method and p-value in AW-Fisher’s method. 
 
Figure 2. True number of concordant DE genes versus the top ranked genes by the 
statistics of 𝑅𝑔






































Top 120 ranked DE genes








































Top 120 ranked DE genes





For simulation scenario 2, Figure 3 demonstrates that our method detects a larger 
number of true DE genes than AW-Fisher method among the top ranked genes. Table 
2 gives some example genes in each of the cross-study DE patterns to compare the 
two methods. For example, a DE gene 77 was assigned (1,1,1,1,1) as the best weight 
in our method but (1,1,0,0,1) in AW-Fisher method. It has large effect sizes (0.95 and 
1.05) and also relatively large p-values (0.28 and 0.26) in the third and fourth study, 
thus ranks high in our method but ranks low in AW Fisher. This shows the advantage 
of our method in equally considering both the statistical and biological significance. 
DE gene 366 ranks higher in our method but ranks low in AW-Fisher mainly because 
AW-Fisher ignores the directionality of effect size.  
 
Figure 3. Number of true DE genes versus the top ranked genes by the statistics of Rg 
=max (𝑅𝑔
+, 𝑅𝑔



























Top 100 ranked genes





Table 2. For each of nine true gene patterns, concluding rank positions and statistical 
information of example genes in adaptively weighted Fisher’s method and our 















77 1,1,1,1,1 101/ 1,1,0,0,1 51/ 1,1,1,1,1 1.91 2.14 0.95 1.05 1.83 0.03 0.02 0.28 0.26 0.03 
125 -1,-1,-1,-1,-1 2/ 1,0,1,1,0 1/ 1,1,1,1,1 -2.23 -1.37 -3.27 -2.48 -1.24 0.01 0.13 0.00 0.01 0.14 
270 1,1,1,1,-1 15/ 1,0,1,1,1 7/ 1,0,1,1,0 1.33 0.42 2.39 3.15 -1.45 0.12 0.64 0.01 0.00 0.08 
366 -1,-1,-1,-1,1 31/ 1,1,1,0,1 17/ 1,1,1,0,0 -1.80 -2.22 -2.64 0.01 1.25 0.04 0.01 0.00 0.99 0.14 
435 1,1,1,-1,-1 52/ 1,0,1,1,1 56/ 1,1,1,0,0 2.80 1.09 1.84 -1.75 -1.26 0.00 0.22 0.04 0.06 0.13 
564 -1,-1,-1,1,1 37/ 0,1,1,1,1 34/ 0,0,0,1,1 0.36 -1.46 -1.31 3.13 1.98 0.68 0.10 0.14 0.00 0.02 
668 1,1,1,0,0 47/ 0,1,1,0,0 12/ 1,1,1,0,0 1.27 2.88 2.16 -0.76 0.08 0.14 0.00 0.01 0.42 0.92 




The Pan-Gynecologic (Pan-Gyn) molecular data from The Cancer Genome Atlas 
(TCGA) project consists of 2579 tumors representing four gynecological types plus 
breast and aims to provide insight into the commonalities and differences across 
multiple tumor lineages (Berger et al. (2018), Weinstein et al. (2013)). We collected 
the data from 1620 cancer patient samples of the “Pan-Gyn” cohort including 299 
OV, 263 UCEC, 306 CESC, 57 UCS, and 695 BRCA samples, with both the RNA-
seq data and the clinical outcomes available. We first merged the RNA-seq data of 
the five cancer types (regarded as studies in our meta-analysis framework) by 
matching the gene symbols and implementing quantile normalization to force the 
distributions to be the same across all five datasets. Genes with mean expression 





were filtered out, and 7127 genes remained. We applied a log2 transformation for the 
data for statistical analysis.  
Results  
Table 3 showed the number of genes, total sample size and the number of dead/alive 
samples (defined from the overall survival data) of each cancer type. 
Table 3. Descriptive analysis of real data set 
TCGA tumor types OV UCEC CESC UCS BRCA 
Mean>1 and 
Variance>Q2 
10093 10069 10186 10243 10043 
Total sample size 
(Dead/Alive) 
299(182/117) 263(38/225) 306(73/233) 57(35/22) 695(89/606) 
Censoring rate 39.13% 85.56% 76.14% 62.86% 87.19% 
 
A total of 26 different weight categories were determined by our measures (Table 4).  
Table 4. Weight categories gained by Rg =max (𝑅𝑔
+, 𝑅𝑔
−)) in our measures. 
Weight pattern Count Weight pattern Count 
0 0 0 1 1 656 0 0 1 1 1 717 
0 0 1 0 1 371 0 1 0 1 1 250 
0 0 1 1 0 805 0 1 1 1 0 339 
0 1 0 0 1 238 1 0 0 1 1 367 
0 1 0 1 0 262 1 0 1 0 1 216 
0 1 1 0 0 158 1 0 1 1 0 339 
0 1 1 0 1 268 1 1 0 0 1 186 
1 0 0 0 1 328 1 1 0 1 0 154 
1 0 0 1 0 388 1 1 1 0 0 141 
1 0 1 0 0 146 0 1 1 1 1 136 
1 1 0 0 0 110 1 0 1 1 1 201 
1 1 0 1 1 71 1 1 1 1 0 105 





The heatmaps of standardized log2-fold change show the representative weight 
categories of genes with adaptively weighted Fisher’s p-values less than 0.05 by 
using 𝑅𝑔
+ (Figure 4) and 𝑅𝑔
− (Figure 5). Figure 6 and 7 zoomed in to two specific 
weight categories. We can see weights were assigned to the studies: BRCA, CESC 
and UCEC which are having small p-values. Our measures also assign weight to the 
study UCS which having relatively larger p-values but with large effect size. Table 3 
shows the sample size of UCS is 57 that limits statistical power, partly explained why 
UCS usually have large effect size but not significance p-values. Our measure 
considered absolute magnitude of effect size to avoid overlooking some important 
genes in study UCS. For the 35 genes shown in figure 6, the direction of effect size of 
all studies except for OV are up-regulated. Figure 7 shows the direction of effect size 






Figure 4. Heatmap of standardized log2-fold change values showing representative 








Figure 5. Heatmap of standardized log2-fold change values showing representative 























Figure 6. Heatmap of -log10(p-values) and effect sizes (log2-fold change) for 35 
genes identified as a weight pattern (1,0,1,1,1) for study BRCA, OV, CESC, UCEC, 





























Figure 7. Heatmap of -log10(p-values) and effect sizes (log2-fold change) for 9 
genes identified as a weight pattern (1,1,1,1,1) for study BRCA, OV, CESC, UCEC, 
USC.  
Figure 8 shows a volcano plot of three example genes “ATF5”, “MX2” and 
“CRYAB”, all have (0,0,0,1,1) as the best estimated weight by our method. It can be 
clearly seen that all of these three genes in the UCS (orange color) and UCEC (blue 
color) have relatively large absolute magnitude of effect sizes and also relatively 






BRCA-green | OV-red | CESC-black | UCEC-blue | UCS-orange 
Figure 8. The volcano plot of three example genes “ATF5”, “MX2” , and “CRYAB” 
identified as a weight pattern: (1,0,0,0,1) by Rg=max(𝑅𝑔
+, 𝑅𝑔
−) for study BRCA, OV, 
CESC, UCEC, UCS. 
Pathway analysis 
After obtaining different weight categories, we performed pathway enrichment 
analysis on each weight category separately using Fisher’s exact test, focusing on 
pathway sizes larger than 10 from four pathway database: Biocarta Pathway 
(http://www.biocarta.com/), Gene Ontology (GO; www.geneontology.org) , Kyoto 
encyclopedia of genes and genomes (KEGG; http://www.genome.jp/kegg/), and 
Reactome (https://reactome.org/). We used a Venn diagram to compare the top 100 
pathways enriched by each of the four weight categories. The overlapping part has 





different categories of biomarkers identified by our method may imply different 
functional domains of biological interest.    
 
Figure 9. The Venn diagram of pathway intersections with pathway sizes larger than 
10 among top 100 pathways enriched by each of the four weight categories 
((1,1,1,1,1), (0,1,1,1,1), (0,0,1,1,1) and (0,0,1,0,1)) identified by using 
Rg=max(𝑅𝑔
+, 𝑅𝑔





Chapter 4: Discussion and Conclusion 
The proposed research is highly responsive to a comprehensive method to categorize 
inter-study heterogenous biomarkers by simultaneously considering statistical 
significance (p-values), biological significance (absolute magnitude of effect size) 
and up-/down-regulated concordance (direction of effect size). Our main findings 
from the simulation and real data analysis shows that more true concordant (up or 
down-regulated) genes were identified and ranked higher in our method as compared 
to the AW Fisher method. In the real application, small sample size studies having 
both large absolute magnitude of effect size and relatively large p-values in most 
genes were also assigned weights in our method as compared to the AW Fisher 
method. The new biomarker categories found in our method may be used for 
predicting the properties or classes of new samples and offer biologically meaningful 
information for future precision medicine. 
There are three limitations of our measures. First, our method cannot distinguish 
whether a gene is DE gene or non-DE gene. In our study, the DE genes were 
determined by adaptively weighted Fisher’s p-values (<0.05). We will derive a p-
value for our concordance statistics by applying empirical procedures like 
permutation or bootstrapping for better inference and gene ranking in the future. 
Multiple testing issue will also need to be addressed once we have a p-value in the 
method. In real application, we have 7127 hypotheses to test, and a significance level 
of 0.05. The probability of observing at least one significant result is 100% (1-(1-
0.05)7127), meaning we have a 100% chance of observing at least one significant 





be applied to correct for the multiplicity. Secondly, we assume the simplest scenario 
where genes are independent from each other. In the future, we will consider 
dependence among the genes in the weight categorization. Thirdly, is the number of 
weigh category is impacted by the number of studies in our measure due to 2K-1 
possibilities of 𝑤𝑔𝑘. The more studies are included in our measure, the more 
possibilities of weight patterns that we would have, and the heavier the computation. 
In the future, we will develop efficient algorithm for a fast selection of best weight 
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